BSE filing, NSE: CONCORD. Summary written from the filing by ALFA Finder's alert engine.
Concord Drugs Ltd: key numbers
- Share price
- ₹64.01
- Market cap
- ₹84.33 Cr
- Revenue (annual)
- ₹78.74 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 41.1×Sector 46.1×
- Promoter holding
- 45.08%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Drugs Ltd
All →Concord Drugs Other Announcement
Concord Drugs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per SEBI regulations.
Concord Drugs Annual General Meeting
Concord Drugs Limited held its 31st Annual General Meeting on September 30, 2026. The meeting covered adoption of financial statements, director appointments, and auditor re-appointment.
Concord Drugs Other Announcement
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Annual Report
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs Annual General Meeting
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.
Concord Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 1000.0% YoY
Concord Drugs Ltd reported revenue from operations of ₹20.9 Cr (+53.7% YoY) and net profit of ₹1.1 Cr (+1000.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +1000.0% YoY
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.